专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080132476A1 SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS 审中-公开
标题翻译：取代的ESTRATRIRIES作为选择性活动的ESTROGENS
公开(公告)号：US20080132476A1
公开(公告)日：2008-06-05
申请号：US12027618
申请日：2008-02-07
申请人： Dirk KOSEMUND , Gerd Mueller , Alexander Hillisch , Karl-Heinrich Fritzemeier , Peter Muhn
发明人： Dirk KOSEMUND , Gerd Mueller , Alexander Hillisch , Karl-Heinrich Fritzemeier , Peter Muhn
IPC分类号： A61K31/56 , A61P19/08 , A61P15/08 , A61P5/24 , A61P15/02 , A61P19/02 , A61P17/06 , A61P9/00 , A61P9/12 , A61P25/28
CPC分类号： C07J41/00 , Y10S514/825 , Y10S514/843
摘要： This invention describes the new 9α-substituted estratrienes of general formula I in which R3, R7, R7′, R13, R16 as well as R17 and R17′ have the meanings that are indicated in the description and R9 means a straight-chain or branched-chain, optionally partially or completely halogenated alkenyl radical with 2 to 6 carbon atoms, an ethinyl or prop-1-inyl radical, as pharmaceutical active ingredients that exhibit in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo preferably a preferential action on the ovary in comparison to the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds.The invention also describes the use of these compounds for treating estrogen-deficiency-induced diseases and conditions.
摘要翻译：本发明描述了通式I的新的9α-取代的雌三烯，其中R 3，R 7，R 7'，R“ 13，R 16以及R 17和R 17'具有在说明书中指出的含义，是指直链或支链，任选部分或完全卤化的具有2-6个碳原子的烯基，乙炔基或丙-1-炔基，作为在体外表现出的药物活性成分对来自大鼠前列腺的雌激素受体制剂的亲和力高于来自大鼠子宫内和体内的雌激素受体制剂的亲和力，优选与子宫相比优于子宫，其生产，其治疗用途和含有新化合物的药物分配形式的优选作用。本发明还描述了这些化合物用于治疗雌激素缺乏诱导的疾病和病症的用途。

2. 发明授权

US07414043B2 9-α-substituted estratrienes as selectively active estrogens 失效
标题翻译： 9-α-取代的雌三醇作为选择性活性雌激素
公开(公告)号：US07414043B2
公开(公告)日：2008-08-19
申请号：US10458735
申请日：2003-06-11
申请人： Dirk Kosemund , Gerd Mueller , Alexander Hillisch , Karl-Heinrich Fritzemeier , Peter Muhn
发明人： Dirk Kosemund , Gerd Mueller , Alexander Hillisch , Karl-Heinrich Fritzemeier , Peter Muhn
IPC分类号： A61K31/56 , C07J1/00
CPC分类号： C07J41/00 , Y10S514/825 , Y10S514/843
摘要： This invention describes the new 9α-substituted estratrienes of general formula I in which R3, R7, R7′, R13, R16 as well as R17 and R17′ have the meanings that are indicated in the description and R9 means a straight-chain or branched-chain, optionally partially or completely halogenated alkenyl radical with 2 to 6 carbon atoms, an ethinyl or prop-1-inyl radical, as pharmaceutical active ingredients that exhibit in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo preferably a preferential action on the ovary in comparison to the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The invention also describes the use of these compounds for treating estrogen-deficiency-induced diseases and conditions.
摘要翻译：本发明描述了通式I的新的9α-取代的雌三烯，其中R 3，R 7，R 7'，R“ 13，R 16以及R 17和R 17'具有在说明书中指出的含义，是指具有2-6个碳原子的直链或支链，任选部分或完全卤化的烯基，乙炔基或丙-1-茚基，作为在体外表现出的药物活性成分对来自大鼠前列腺的雌激素受体制剂的亲和力高于来自大鼠子宫内和体内的雌激素受体制剂的亲和力，优选与子宫相比优于子宫，其生产，其治疗用途和含有新化合物的药物分配形式的优选作用。本发明还描述了这些化合物用于治疗雌激素缺乏诱导的疾病和病症的用途。

3. 发明申请

US20090029957A1 8-BETA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS 审中-公开
标题翻译： 8-BETA取代的ESTRATRIENES作为选择性活动的ESTROGENS
公开(公告)号：US20090029957A1
公开(公告)日：2009-01-29
申请号：US12171424
申请日：2008-07-11
申请人： Olaf Peters , Nico Braeuer , Ina Thieme , Katja Prelle , Peter Muhn , Karl Heinrich Fritzemeier
发明人： Olaf Peters , Nico Braeuer , Ina Thieme , Katja Prelle , Peter Muhn , Karl Heinrich Fritzemeier
IPC分类号： A61K31/56 , A61K31/565 , C07J1/00 , A61P37/00 , A61P35/00 , A61P17/00 , A61P17/14 , A61P9/00 , A61P1/00
CPC分类号： C07J1/007 , C07J1/0062
摘要： The invention refers to 8β-substituted estra-1,3,5(10)-triene derivatives of general formula I their use as pharmaceutical active ingredients, which have in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo a preferential action in the ovary in comparison to the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds.
摘要翻译：本发明涉及通式I的8-取代的雌-1,3,5（10） - 三烯衍生物，其用作药物活性成分，其具有比雌激素受体制剂在体外对雌激素受体制剂更高的亲和力与子宫相比，子宫中的子宫，其产生，其治疗用途和含有新化合物的药物分配形式相比在体内具有优先的作用。

4. 发明授权

US06790858B2 Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone 失效
标题翻译：喹啉，异喹啉和酞嗪衍生物作为促性腺激素释放激素的拮抗剂
公开(公告)号：US06790858B2
公开(公告)日：2004-09-14
申请号：US10078530
申请日：2002-02-21
申请人： Peter Strehlke , Peter Droescher , Ulrich Buehmann , Norbert Schmees , Peter Muhn , Holger Hess-Stumpp , Roland Kühne , Eckhard Guenther , Emmanuel Polymeropoulos , Antonius M. Ter Laak
发明人： Peter Strehlke , Peter Droescher , Ulrich Buehmann , Norbert Schmees , Peter Muhn , Holger Hess-Stumpp , Roland Kühne , Eckhard Guenther , Emmanuel Polymeropoulos , Antonius M. Ter Laak
IPC分类号： C07D21556
CPC分类号： C07D401/04 , A61K31/47 , C07D215/56 , C07D237/32 , C07D401/12 , C07D409/04
摘要： The present invention relates to a compound of formula (I): where R1-R6, W, X, and Y are defined herein, a composition includung the compound of formula (I), and a method for, e.g., male birth control, including administering an effective amount of a compound of formula (I) to a patient in need thereof.
摘要翻译：本发明涉及式（I）化合物：其中R1-R6，W，X和Y如本文所定义，包括式（I）化合物的组合物以及例如男性避孕方法，包括向有需要的患者施用有效量的式（I）化合物。

5. 发明授权

US07309691B2 Combined pharmaceutical preparation containing LHRH-analogous substances and anti estrogens for treating gynaecological disorders 失效
标题翻译：含有LHRH类似物质和抗雌激素用于治疗妇科疾病的组合药物制剂
公开(公告)号：US07309691B2
公开(公告)日：2007-12-18
申请号：US09117357
申请日：1997-01-29
申请人： Klaus Stöckemann , Peter Muhn
发明人： Klaus Stöckemann , Peter Muhn
IPC分类号： A61K38/00 , A61K31/445
CPC分类号： A61K38/09 , A61K31/445 , A61K31/40 , A61K31/135 , A61K2300/00
摘要： The invention relates to a pharmaceutical combined preparation of LHRH analogues and anti-oestrogens having tissue-selective oestrogen activity and also to its use for the treatment of gynaecological disorders, especially for the treatment of endometrioses and myomas.
摘要翻译：本发明涉及具有组织选择性雌激素活性的LHRH类似物和抗雌激素的药物组合制剂，以及其用于治疗妇科疾病，特别是用于治疗子宫内膜异位症和肌瘤的用途。

6. 发明申请

US20050004127A1 Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone 失效
标题翻译：喹啉，异喹啉和酞嗪衍生物作为促性腺激素释放激素的拮抗剂
公开(公告)号：US20050004127A1
公开(公告)日：2005-01-06
申请号：US10896961
申请日：2004-07-23
申请人： Peter Strehlke , Peter Droescher , Ulrich Buehmann , Norbert Schmees , Peter Muhn , Holger Hess-Stumpp , Roland Kuhne , Eckhard Guenther , Emmanuel Polymeropoulos , Antonius Ter Laak
发明人： Peter Strehlke , Peter Droescher , Ulrich Buehmann , Norbert Schmees , Peter Muhn , Holger Hess-Stumpp , Roland Kuhne , Eckhard Guenther , Emmanuel Polymeropoulos , Antonius Ter Laak
IPC分类号： A61K31/47 , A61P5/02 , C07D215/56 , C07D237/32 , C07D401/04 , C07D401/12 , C07D409/04 , A61K31/502 , A61K31/517
CPC分类号： C07D401/04 , A61K31/47 , C07D215/56 , C07D237/32 , C07D401/12 , C07D409/04
摘要： The invention relates to new quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone.
摘要翻译：本发明涉及作为促性腺激素释放激素拮抗剂的新喹啉，异喹啉和酞嗪衍生物。

7. 发明授权

US07388006B2 Non-steroidal progesting 失效
标题翻译：非甾体类孕酮
公开(公告)号：US07388006B2
公开(公告)日：2008-06-17
申请号：US10384775
申请日：2003-03-11
申请人： Norbert Schmees , Manfred Lehmann , Ulrike Fuhrmann , Peter Muhn , Christa Hegele-Hartung , Michael Klotzbuecher
发明人： Norbert Schmees , Manfred Lehmann , Ulrike Fuhrmann , Peter Muhn , Christa Hegele-Hartung , Michael Klotzbuecher
IPC分类号： A61K31/502 , A61K31/536 , C07D237/32 , C07D265/02
CPC分类号： C07D307/88 , A61K31/365 , A61K31/535 , A61K31/565 , C07D265/02 , A61K2300/00
摘要： The present invention relates to non-steroidal progestins of the general formula (I) wherein R1 and R2 are independently of each other —H or —F, R3 is —CH3 or —CF3, and Ar is or a pharmaceutically acceptable derivative or analogue thereof. These progestins are suitable for selectively modulating progesterone receptor mediated effects in different target tissues, particularly in uterine tissue versus breast tissue. Therefore, the progestins of the present invention, optionally in combination with estrogens, may be used for contraception (in particular in estrogen-free oral contraceptives), hormone replacement therapy and the treatment of gynecological disorders. The present invention furthermore relates to methods for selectively modulating progesterone receptor mediated effects in different target tissues or organs.
摘要翻译：本发明涉及通式（I）的非甾体孕激素，其中R 1和R 2各自独立地为-H或-F，R SUB > 3是-CH 3或-CF 3 N，Ar是其药学上可接受的衍生物或类似物。这些孕激素适合于在不同的靶组织中，特别是在子宫组织与乳腺组织中选择性调节孕激素受体介导的作用。因此，本发明的孕激素，任选地与雌激素组合，可用于避孕（特别是无雌激素的口服避孕药），激素替代疗法和妇科疾病的治疗。本发明还涉及用于在不同靶组织或器官中选择性调节孕酮受体介导的作用的方法。

8. 发明授权

US07378522B2 Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone 失效
标题翻译：喹啉，异喹啉和酞嗪衍生物作为促性腺激素释放激素的拮抗剂
公开(公告)号：US07378522B2
公开(公告)日：2008-05-27
申请号：US10896961
申请日：2004-07-23
申请人： Peter Strehlke , Peter Droescher , Ulrich Buehmann , Norbert Schmees , Peter Muhn , Holger Hess-Stumpp , Roland Kühne , Eckhard Guenther , Emmanuel Polymeropoulos , Antonius M. Ter Laak
发明人： Peter Strehlke , Peter Droescher , Ulrich Buehmann , Norbert Schmees , Peter Muhn , Holger Hess-Stumpp , Roland Kühne , Eckhard Guenther , Emmanuel Polymeropoulos , Antonius M. Ter Laak
IPC分类号： C07D239/72
CPC分类号： C07D401/04 , A61K31/47 , C07D215/56 , C07D237/32 , C07D401/12 , C07D409/04
摘要： The invention relates to new quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone.
摘要翻译：本发明涉及作为促性腺激素释放激素拮抗剂的新喹啉，异喹啉和酞嗪衍生物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式